Cynata Therapeutics Limited

CHIA:CYP Stock Report

Market Cap: AU$36.1m

Cynata Therapeutics Past Earnings Performance

Past criteria checks 0/6

Cynata Therapeutics's earnings have been declining at an average annual rate of -16.2%, while the Biotechs industry saw earnings growing at 13.2% annually. Revenues have been declining at an average rate of 7.6% per year.

Key information

-16.2%

Earnings growth rate

-3.5%

EPS growth rate

Biotechs Industry Growth9.6%
Revenue growth rate-7.6%
Return on equity-135.0%
Net Margin-420.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

No updates

Recent updates

Revenue & Expenses Breakdown

How Cynata Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

CHIA:CYP Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 242-1029
31 Mar 242-12211
31 Dec 232-14212
30 Sep 232-14212
30 Jun 232-14212
31 Mar 232-12211
31 Dec 223-929
30 Sep 225-729
30 Jun 228-539
31 Mar 228-556
31 Dec 218-474
30 Sep 215-654
30 Jun 212-834
31 Mar 212-725
31 Dec 203-606
30 Sep 205-516
30 Jun 207-426
31 Mar 206-636
31 Dec 194-846
30 Sep 193-836
30 Jun 191-826
31 Mar 191-724
31 Dec 181-623
30 Sep 181-523
30 Jun 181-513
31 Mar 181-513
31 Dec 171-513
30 Sep 172-513
30 Jun 172-513
31 Mar 172-414
31 Dec 162-304
30 Sep 161-414
30 Jun 161-514
31 Mar 161-523
31 Dec 151-532
30 Sep 151-422
30 Jun 150-412
31 Mar 150-321
31 Dec 140-321
30 Sep 140-321
30 Jun 140-321
31 Mar 140-320
31 Dec 130-210

Quality Earnings: CYP is currently unprofitable.

Growing Profit Margin: CYP is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: CYP is unprofitable, and losses have increased over the past 5 years at a rate of 16.2% per year.

Accelerating Growth: Unable to compare CYP's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CYP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (7.1%).


Return on Equity

High ROE: CYP has a negative Return on Equity (-135.02%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 14:59
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Cynata Therapeutics Limited is covered by 5 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dennis HulmeAPP Securities Pty Ltd.
Raghuram SelvarajuH.C. Wainwright & Co.
Chris KallosMST Financial Services Pty Limited